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1. Introduction 
It has recently been shown that the formation of 
the inactive complex between thrombin and the plasma 
protease inhibitor antithrombin is accompanied by 
the production of a proteolytically modified form of 
antithrombin [ I]. This modified inhibitor has lost all 
or most of the ability to inhibit thrombin and has a 
reduced affinity for heparin. In urea~polyac~iamide 
gel electrophoresis of the modified ~tithrombin, 
only two polypeptide fragments with apparent molec- 
ular weights of -50 000 and 5000 were seen [if. This 
indicated that the modification by thrombin which 
produces this inactive antithrombin species i  restricted 
to the scission of one or at most a few adjacent pep- 
tide bonds near one of the ends of the antithrombin 
polypeptide chain. The two peptide chain segments 
which result from this cleavage are held together by 
one or more disulfide bonds, Sub~quent investiga- 
tions showed that a protein which electrophoretically 
was indistinguishable from the free thrombin-mob- 
fied form of antithrombin could be released from the 
antithrombin-thrombin complex by various proce- 
dures [2,3]. It was therefore suggested that the throm- 
bin-sensitive bond or bonds of antithrombin are 
located in the active site region of the molecule. This 
proposition is further supported by the results pre- 
sented here. We show that the free modified form of 
bovine ~ti~rornb~ has only a single thrombin cleav- 
age site, which is at an Arg-Ser bond near the C-ter- 
minal end of the chain. This thrombin cleavage site 
is identical to the site of chain cleavage in the modi- 
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fied form of the inhibitor which can be released from 
the anti~rombin-thrombin complex. 
2, Materials and methods 
Free thrombin-modified bovine antithrombin and 
bovine antithrombln-thrombin complexes were pre- 
pared as described in f 1,3]. 
The antithrombin-thrombin complex was dis- 
sociated by 1 M hy~oxyl~ine (pH 7.6) in 0.1% 
sodium dodecyl sulphate under non-reducing condi- 
tions [3,4]. The modified antithrombin released from 
the complex by this treatment was separated from 
undissociated complex and liberated thrombin by gel 
chromatography onSephacryl S-200 in 0.05% dodecyl 
sulphate [3]. 
Modified antithrombin, free or released from the 
antithromb~-thromb~ complex, was reduced at 
S-10 g protein/l by 10 mM dithio~reitol in 0.1 M 
Tris buffer (pH 8.4) in the presence of dodecyl sul- 
phate. The amount of dodecyl sulphate used was 
3-times the weight of the protein. After reduction 
overnight, he solution was carboxymethylated in 
the dark by the addition of iodo-[ l-‘4C]acetate (spec. 
act. -4000 dpm/nmol) to 25 mM final cont. Excess 
iodoacetate was destroyed after 1 h by additional 
dithio~reitol, and the solution was dialysed overnight 
against 0.05 M Tris buffer (pH 7.5) conta~ing 0.1 M 
NaCl, 0.05% dodecyl sulphate and 5 mM /3-mercapto- 
ethanol. 
Samples for amino acid analyses were hydrolyzed 
in evacuated tubes for 24 h or 72 h at 110°C with 
6 M HCl containing 0.1% phenol. Amino acids were 
~lse~ier~~orth-~olla~d Biomedical Press 
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determined on a Beckman 12 1 M amino acid analyzer. 
N-Terminal amino acids were determined with the 
dansyl method, and the dansyl derivatives were iden- 
tified on polyamide layers in 4 chromatographic sys- 
tems, as in (5 1. 
threitol. The two polypeptide-containing fractions 
were pooled separately, dialysed for 24 h against 
several changes of water and lyophilised. The lyo- 
philised material may have contained some residual 
dodecyl sulphate. 
A Beckman 890C instrument was used for liquid- 
phase sequencer analyses. Polybrene [6,7] was added 
as a carrier, together with glycine, and 2 cycles were 
then performed before peptide application. A 1 M 
Quadrol protein program was used for the large pep- 
tide of modified antithrombin, and a 0.1 M Quadrol 
peptide program was employed for the small pep- 
tide. High-performance liquid chromatography of 
phenyl~iohydanto~ derivatives was carried out in a 
Hewlett-Packard 1084 B instrument on a W-8 reverse 
phase column with a gradient of 0.01 M sodium ace- 
tate (pH 4.5) and acetonitrile [S]. Thin-layer chro- 
matography was done on fluorescent-coated silica 
gels in xylene:isopropanol(7:2, v/v). After a first 
identification of the derivatives, their positions were 
additionally checked by staining the plate with 0.1% 
ninhydrin in ethanol:collidine (9.55, v/v) [9]. 
3, Results and discussion 
Amino-acid analyses of the isolated chains of free 
modified antithrombin (table 1) show that the sum of 
the compositions of the two chains agrees remarkably 
well with the composition of intact antithrombin. The 
small differences that are seen are within the variation 
expected from the experimental conditions, especially 
since the isolated chains were analysed after only a 
single time of hydrolysis (24 h), whereas the values 
for intact antithrombin were derived from analyses 
after different imes of hydrolysis (24 h and 72 h). 
Con~quently, the hydrolytic destruction and slow 
release of certain amino acids are not compensated 
for in the values for the sum of the chains. The excel- 
lent agreement between the amino acid composition 
of the intact molecule and the sum of the composi- 
tions of the two chains uggests hat, together, the 
isolated large and small fragments of modified anti- 
thrombin account for the whole antithrombin poly- 
peptide chain. This supports the conclusion from the 
previous electrophoretic studies that thrombin cleaves 
the antithrombin molecule at one site only [1,3]. 
The large and small polypeptide chains of either The thrombin cleavage site in free modified anti- 
free modified bovine antithrombin, or the modified thrombin was localised by N-terminal sequence analy- 
form of the protein which was released from the ses of the isolated large and small polypeptide chains 
antithrombin-thrombin complex and subsequently in a liquid-phase sequencer. Initial coupling in the 
purified, were separated by gel chromatography. The analyses was -50% and the repetitive yields -94%. 
reduced and [r4C]carboxymethylated proteins The results are shown in table 2, which also includes 
(5-10 mg) were applied to a 1.6 X 90 cm column of a comparison with the known st~ctures of the homol- 
Sephacryl S-200 in 0.05 M Tris buffer (pH 7.5) con- ogous parts of intact human antithromb~ [lo], and 
taining 0.1 M NaCl and 0.05% sodium dodecyl sul- with the known N-terminal sequence of the bovine 
phate. Three radioactive peaks were obtained by this protein [ 111. The N-terminal sequence of the large 
procedure. Two of these appeared at the expected chain of free modified bovine antithrombin was found 
elution positions of polypeptides with mol. wt to be identical to the N-terminal sequence of the 
-50 000 and 5000. Moreover, the material in these intact protein (table 2). Moreover, the N-terminal 
peaks migrated as the large and small polypeptides of sequence of the small chain of the modified bovine 
modified antithrombin, respectively, in dodecyl sul- protein is clearly homologous with the residues which 
phatetpolyacrylamide and urea/polyac~lamide g l start at the position with tentative no. 386 in the 
electrophoresis [ 1,3]. A third minor gel chromato- intact human protein (table 2). This shows that free 
graphic peak eluted at the total volume of the column modified antithrombin is produced by thrombin 
and contained no material that could be identified in cleavage in the C-terminal end of the antithrombin 
either type of electrophoresis. It was therefore con- polypeptide chain. This cleavage liberates Ser-386 as 
cluded that this peak consisted only of residual reac- the N-terminus of the small fragment and residue 385, 
tion products between iodoacetic acid and dithio- which is Arg in the human [lo] and presumably also 
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Table 1 
Amino acid compositions of the large and small polypeptide chains of free modified 
bovine antithrombin and of intact antithrombin (mol amino acids/m01 polypeptide)a 
Residue Large Small Sum of large Intact Difference between 
chainb chainb and smaII chains antithrombinC sum of chains and 
intact antithrombin 
CysCm 4.0 0.9 4.9 6.Sd -1.6 
Asx 42.5 5.4 47.9 47.4 0.5 
Thr 23.3 2.0 25.3 26.1 -0.8 
Ser 30.7 3.4 34.1 36.2 -2.1 
Glx 54.9 1.3 56.2 53.8 2.4 
Pro 18.0 2.0 20.0 18.2 1.8 
ClY 18.6 2.3 20.9 17.8 3.1 
Ala 21.4 2.9 30.3 30.3 0 
Val 26.9 3.9 30.8 29.7 1.1 
Met 10.0 0.7 10.7 10.7 0 
Ile 23.9 1.7 25.6 23.6 2.0 
Leu 34.3 3.1 31.4 40.8 -3.4 
Tyr 10.7 - 10.7 10.0 0.7 
Phe 25.2 2.6 21.8 27.0 0.8 
Lys 32.4 1.5 33.9 32.0 1.9 
His 5.7 0.1 5.8 6.3 -0.5 
Arg 21.5 2.7 24.2 24.0 0.2 
Sum 410.0 36.5 446.5 440.4 -8.4 
+14.5 
a The values given are based on mol. wt 56 000 (including 9.8% carbohydrate) for the 
intact molecule [ 131 and on fragment sizes estimated from the cleavage site identified 
in this work. Tryptophan was not determined 
b Determined after a 24 h hydrolysis 
c Average of 3 determinations, each after a 24 h and a 72 h hydrolysis. Corrected for 
destruction of Thr and Ser. 72 h value used for Val and Be 
d Value for C&s, determined as Cys-SO,H after performic acid oxidation 
in the bovine protein, as the C-terminus of the large 
fragment. The position of the cleavage site is consis- 
tent with the sizes of the fragments (see above and 
[l]), with the compositions of the fragments (table 1) 
in relation to the sequence of the intact protein [lo], 
and with the known specificity of thrombin for cleav- 
age at arginyl bonds. 
In order to further verify the cleavage site and to 
ascertain that small fragments from possible additional 
cleavages have not escaped detection, free modified 
bovine antithrombin was submitted to direct sequencer 
analysis without reduction or separation of the chains. 
Degradation of -100 nmol protein was found to pro- 
duce 2 residues in each cycle, both in similar yield 
(-60 nmol) and both exactly those shown for the 
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small and large chains in table 2. Moreover, due to the 
large amount analyzed, all early residues, including 
Arg in position 2 of the large chain (cf. table 2), were 
positively identified, and the amino acid sequences 
could be followed longer than shown in table 2. All 
residues but 3 were thus identified up to position 22 
in both chains. This analysis of the whole modified 
antithrombin molecule confirms the presence of only 
1 cleavage site of the polypeptide chain and verifies 
the position of this site. It is obvious that direct 
sequencer analysis of peptide mixtures is a good 
method to evaluate the number of fragments obtained 
by limited proteolytic cleavage, especially when a 
protein with known primary structure is cleaved. The 
same approach has been used to show as many as 3 
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Table 2 
Amino acid sequences of the N-terminal parts of the isolated large and small chains from free modified 
antithrombin, compared to predetermined sequences for the intact human and bovine proteins 
1 5 8 
Present analysis His-(Arg)-Se-Pro -Val -Glu -Asp -Val - 
of bovine large H T H,T H,T H,T H,T H,T 
chain ~--J-.I---I~-J~__J 
15 10 
Known structure at 1 5 8 
positions l-8 of Bovine [ 121 His- Arg -Ser-Pro -Val -Glu -Asp -Val - 
intact antithrombin Human [lo] His- Gly -Ser-Pro -Val -Gap -Asp -Be - 
1 5 10 
Present analysis Ser -Leu -Asn -Ser -Asp -Arg-Val -Thr -Phe -Lys-Ala -Asn - 
of bovine small D,T H,T H,T H,T H,T H H,T H,T H,T T H,T H,T 
chain --_I ---\ ---I -_-J 1. _-J _I -_-J -1-_-I-_1 
25 20 20 15 
Known structure at 385 390 395 
tentative positions Arg-Se-Leu-Asn-Pro-Asn-Arg-Val-Thr-Phe-Lys-Ala-Asn 
385-397 of intact 
human antithrombin 
1101 
Letters indicate methods of identification of residues. D, N-terminus by dansyl method; H and T, high-per- 
formance liquid chromatography and thin-layer chromatography, respectively, of phenylthiohydantoin 
derivatives. Figures below arrows show levels of nanomoles recovered. The residue within brackets was not 
unambiguously determined in the isolated large chain, but was identified on direct analysis of modified anti- 
thrombin without chain separation (see text) and is also known before [ 121 
cleavage sites in a still larger protein, the adenovirus 
hexon [Ill. 
The results also show that the homology between 
the bovine and human antithrombins is quite extensive, 
in agreement with [ 121. Two new replacements between 
the 2 proteins have been characterized in this work, 
i.e., Pro/Ser and Asn/Asp at positions 389 and 390, 
respectively (table 2). In addition, a third replacement 
(not reported in table 2) was found, namely Phe/L.eu 
at position 403. Moreover, the deletion at position 6, 
as well as the exchanges at positions 2 and 8 [ 121 were 
confirmed (table 2). In total, 41 positions in the 2 
proteins have now been compared ([ 121, and this 
report), which identify 5 amino acid exchanges and 
one deletion. The exchanges are compatible with one- 
base mutations, and, if representative for the entire 
molecule, suggest an 85% identity between human 
and bovine antithrombin. 
The N-terminal sequence of the small chain of the 
modified form of antithrombin which was released 
by hydroxylamine from the antithrombin-thrombin 
complex was also analyzed. It was followed in the 
sequencer for 8 cycles. The residues obtained were 
the same as those for the small chain of the free pro- 
tein shown in table 2. Thus the thrombin cleavage 
site in free modified antithrombin and the site of 
chain cleavage in the modified form of the inhibitor 
released from the complex are identical. This finding 
lends further support to the proposal that the amino 
acid sequence around the cleavage site in the modi- 
ficd antithrombin molecule is in the active site region 
of the intact inhibitor [3]. 
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